ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) OPTIONS

These side effects have been notably milder when compared with an inhibitor of both bromodomains. A detailed molecular Examination also revealed that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes.  ― Stephen Taylor88 These preclinical studies provide paradigms for potential clinical trials in AML, and